A detailed history of American International Group, Inc. transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, American International Group, Inc. holds 37,779 shares of AVIR stock, worth $125,048. This represents 0.0% of its overall portfolio holdings.

Number of Shares
37,779
Previous 38,104 0.85%
Holding current value
$125,048
Previous $116,000 31.03%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

SELL
$3.09 - $4.56 $1,004 - $1,481
-325 Reduced 0.85%
37,779 $152,000
Q4 2023

Feb 13, 2024

SELL
$2.8 - $3.35 $431 - $515
-154 Reduced 0.4%
38,104 $116,000
Q3 2023

Nov 13, 2023

BUY
$3.0 - $3.79 $4,080 - $5,154
1,360 Added 3.69%
38,258 $114,000
Q2 2023

Aug 04, 2023

BUY
$3.21 - $5.06 $231 - $364
72 Added 0.2%
36,898 $137,000
Q1 2023

May 12, 2023

BUY
$3.0 - $4.97 $2,199 - $3,643
733 Added 2.03%
36,826 $123,000
Q4 2022

Feb 10, 2023

SELL
$4.35 - $6.17 $569 - $808
-131 Reduced 0.36%
36,093 $173,000
Q3 2022

Nov 14, 2022

BUY
$5.49 - $8.79 $2,810 - $4,500
512 Added 1.43%
36,224 $206,000
Q2 2022

Aug 12, 2022

BUY
$5.33 - $8.18 $19,438 - $29,832
3,647 Added 11.37%
35,712 $254,000
Q1 2022

May 13, 2022

SELL
$5.5 - $9.19 $12,413 - $20,741
-2,257 Reduced 6.58%
32,065 $232,000
Q4 2021

Feb 11, 2022

SELL
$7.67 - $44.59 $7,877 - $45,793
-1,027 Reduced 2.91%
34,322 $307,000
Q3 2021

Nov 12, 2021

SELL
$21.33 - $35.06 $17,917 - $29,450
-840 Reduced 2.32%
35,349 $1.24 Million
Q2 2021

Aug 13, 2021

BUY
$19.22 - $59.08 $533,105 - $1.64 Million
27,737 Added 328.17%
36,189 $777,000
Q1 2021

May 07, 2021

BUY
$41.42 - $88.44 $952 - $2,034
23 Added 0.27%
8,452 $522,000
Q4 2020

Feb 12, 2021

BUY
$26.36 - $41.78 $222,188 - $352,163
8,429 New
8,429 $352,000

Others Institutions Holding AVIR

About Atea Pharmaceuticals, Inc.


  • Ticker AVIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,258,600
  • Market Cap $276M
  • Description
  • Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...
More about AVIR
Track This Portfolio

Track American International Group, Inc. Portfolio

Follow American International Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on American International Group, Inc. with notifications on news.